Dementia and Alzheimer Disease

Epilepsy

Headache and Migraine

Movement Disorders

Multiple Sclerosis

Neuromuscular

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

International Journal of MS Care

Resources

Disease Spotlight

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

eNewsletter

Print Subscription

Articles

A cross-sectional and longitudinal comparative analysis suggests a subclinical neurodegenerative process may occur in MOG antibody disease based on a distinct pattern of brain atrophy.

Whole Brain Volume Loss, Higher Thalamic and Hippocampal Atrophy Rate Identified in MOGAD

Data from a cohort of more than 8000 participants suggest that older adults with less optimal sleep duration might benefit from moderate napping for their cognitive functions.

Moderate Napping Shows Protective Effects Against Cognitive Decline

Videos

The pediatric neurologist at Nationwide Children's Hospital talked about the year-over-year changes in day-to-day clinical practice of patients with epilepsy. [WATCH TIME: 4 minutes]  

Shift in Day-to-Day Practices in Epilepsy Care: Anup Patel, MD

Case Study and Overview of WAKIX® (pitolisant) Tablets in the Treatment of Excessive Daytime Sleepiness and/or Cataplexy in Adults with Narcolepsy

, has been with the team since October 2019. Follow him on Twitter 

In addition to showing a tolerable safety profile, EQU-001 resulted in reduced IL-17 and IL-1b plasma levels relative to baseline and limited the ability of peripheral mononuclear cells to secrete additional pro-inflammatory cytokines.

Antiseizure Agent EQU-001 Shows Safety, Tolerability, and Preliminary Efficacy in Phase 2 Study

The chief training and education officer at the Parkinson’s Foundation provided perspective on a recently launched online program aimed at educating healthcare professionals. [WATCH TIME: 3 minutes]

Understanding Parkinson’s Foundation’s New Community Education Series: Eli Pollard

After 12 weeks of treatment, almost twice as many patients on eptinezumab reported either “much improved” or “very much improved” than those on placebo, according to Patient Global Impression of Change. 

Eptinezumab Shows Positive Effects on Patient-Reported Outcomes in Medication-Overuse Headache from Chronic Migraine

The director of the Headache Center at Allegheny Health Network provided an overview of clinically relevant approaches to treat migraine at its core pathology. [WATCH TIME: 2 minutes]

Emerging Concepts in Migraine and Targeting PACAP: Dolores Santamaria, MD

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

Twitter

LinkedIN

Spotlight

NMOSD

Narcolepsy

Parkinson Disease

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

 video series brings together pairs of expert clinicians and physicians to discuss the latest and most up-to-date clinical care for specific neurologic diseases and disorders.

1rem

Experts review the challenges of managing OFF episodes in Parkinson's disease and the current treatment options to optimize therapy. 

Optimal Management of OFF Episodes in Parkinson's Disease

Overview of OFF Episodes in Parkinson’s Disease

Apomorphine Subcutaneous Injection: Historical Perspective for Off-Episodes in Parkinson’s Disease

Apomorphine Subcutaneous Injection: Efficacy and Administration for Off-Episodes in Parkinson Disease

Apomorphine Subcutaneous Injection: Patient Selection for Off-Episodes in Parkinson Disease

Apomorphine Subcutaneous Injection: Circle of Care Program for Off-Episodes in Parkinson Disease

Recent Approval of Sublingual Apomorphine for Off-Episodes in Parkinson Disease

Continuous Subcutaneous Apomorphine Infusion in Development for OFF Episodes in Parkinson’s Disease

Levodopa Inhalation Powder for OFF Episodes in Parkinson’s Disease

Recently Approved Oral Therapies for OFF Episodes in Parkinson’s Disease

Device-Assisted and Surgical Options for Advanced Motor Fluctuations in Parkinson’s Disease

Treating OFF Episodes in Parkinson’s Disease During COVID-19